KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Deferred Tax (2020 - 2026)

Pacira BioSciences has reported Long-Term Deferred Tax over the past 7 years, most recently at $122.1 million for Q1 2026.

  • For Q1 2026, Long-Term Deferred Tax fell 5.34% year-over-year to $122.1 million; the TTM value through Mar 2026 reached $122.1 million, down 5.34%, while the annual FY2025 figure was $123.9 million, 5.0% down from the prior year.
  • Long-Term Deferred Tax for Q1 2026 was $122.1 million at Pacira BioSciences, down from $123.9 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $169.3 million in Q1 2022 and troughed at $120.2 million in Q3 2025.
  • A 5-year average of $143.3 million and a median of $141.1 million in 2024 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: skyrocketed 69.52% in 2022 and later dropped 15.82% in 2024.
  • Year by year, Long-Term Deferred Tax stood at $160.3 million in 2022, then fell by 9.87% to $144.5 million in 2023, then dropped by 9.77% to $130.4 million in 2024, then dropped by 5.0% to $123.9 million in 2025, then decreased by 1.4% to $122.1 million in 2026.
  • Business Quant data shows Long-Term Deferred Tax for PCRX at $122.1 million in Q1 2026, $123.9 million in Q4 2025, and $120.2 million in Q3 2025.